Cytomegalovirus infection in patients with haematological diseases and after autologous stem cell transplantation as consolidation: a single-centre study

Klára Piukovics, Gabriella Terhes, Tímea Gurbity-Pálfi, Ágnes Bereczki, Ferenc Rárosi, Judit Deák, Zita Borbényi, E. Urbán

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Because of the widespread use of immunosuppressive drugs, CMV infection is one of the most important causes of morbidity and mortality in patients with haematological malignancies worldwide. The aim of the study was to retrospectively analyse the epidemiology of CMV infection in haematological patients. Between 2008 and 2014, 1238 quantitative CMV DNA detections from plasma specimens were performed. These specimens were collected from 271 patients with haematological malignancy. Patients were grouped on the basis of underlying diseases (lymphoid and myeloid malignancies and other haematological diseases). In the lymphoid and myeloid groups, we distinguished ASCT and non-ASCT groups. During the studied period, the majority of examined patients (82.6 %) were treated with lymphoproliferative disease. A total of 126 (46.5 %) patients underwent ASCT, while 145 (53.5 %) did not have stem cell transplantation. A total of 118 (9.5 %) of 1238 plasma specimens proved to be positive for CMV DNA; these specimens were collected from 66 (24.4 %) patients. Twenty-four (16.6 %) of 145 non-ASCT patients had CMV PCR positive specimens. Among non-ASCT patients with positive CMV PCR results, 10 patients were asymptomatic, 14 had symptomatic reactivation, while 2 had CMV disease. In the ASCT group, 42 (33.3 %) patients had CMV PCR positive samples. CMV reactivation was asymptomatic in 34 (81 %) cases, and 8 (19 %) patients had symptomatic reactivation. In the non-ASCT group, the rate of CMV infection is low. In the ASCT group, the prevalence of CMV infection was higher than in the non-ASCT group, but the majority of CMV infection was asymptomatic and only small number of patients had symptomatic reactivation. Thus, our results also showed that the use of routine CMV DNA monitoring is not necessary in patients with haematological malignancies not receiving fludarabine-containing regimen or alemtuzumab, in spite of this to decrease the mortality we have to consider the use of molecular tests in case of suspected infectious conditions.

Original languageEnglish
Pages (from-to)125-131
Number of pages7
JournalAnnals of Hematology
Volume96
Issue number1
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Hematologic Diseases
Cytomegalovirus Infections
Stem Cell Transplantation
Hematologic Neoplasms
Infection
Polymerase Chain Reaction
DNA
Asymptomatic Infections
Mortality
Immunosuppressive Agents
Epidemiology

Keywords

  • Cytomegalovirus
  • Diagnosis
  • Immunocompromised
  • Molecular

ASJC Scopus subject areas

  • Hematology

Cite this

Cytomegalovirus infection in patients with haematological diseases and after autologous stem cell transplantation as consolidation : a single-centre study. / Piukovics, Klára; Terhes, Gabriella; Gurbity-Pálfi, Tímea; Bereczki, Ágnes; Rárosi, Ferenc; Deák, Judit; Borbényi, Zita; Urbán, E.

In: Annals of Hematology, Vol. 96, No. 1, 01.01.2017, p. 125-131.

Research output: Contribution to journalArticle

Piukovics, Klára ; Terhes, Gabriella ; Gurbity-Pálfi, Tímea ; Bereczki, Ágnes ; Rárosi, Ferenc ; Deák, Judit ; Borbényi, Zita ; Urbán, E. / Cytomegalovirus infection in patients with haematological diseases and after autologous stem cell transplantation as consolidation : a single-centre study. In: Annals of Hematology. 2017 ; Vol. 96, No. 1. pp. 125-131.
@article{3fb6d593c0a742969d82643dc1ee3928,
title = "Cytomegalovirus infection in patients with haematological diseases and after autologous stem cell transplantation as consolidation: a single-centre study",
abstract = "Because of the widespread use of immunosuppressive drugs, CMV infection is one of the most important causes of morbidity and mortality in patients with haematological malignancies worldwide. The aim of the study was to retrospectively analyse the epidemiology of CMV infection in haematological patients. Between 2008 and 2014, 1238 quantitative CMV DNA detections from plasma specimens were performed. These specimens were collected from 271 patients with haematological malignancy. Patients were grouped on the basis of underlying diseases (lymphoid and myeloid malignancies and other haematological diseases). In the lymphoid and myeloid groups, we distinguished ASCT and non-ASCT groups. During the studied period, the majority of examined patients (82.6 {\%}) were treated with lymphoproliferative disease. A total of 126 (46.5 {\%}) patients underwent ASCT, while 145 (53.5 {\%}) did not have stem cell transplantation. A total of 118 (9.5 {\%}) of 1238 plasma specimens proved to be positive for CMV DNA; these specimens were collected from 66 (24.4 {\%}) patients. Twenty-four (16.6 {\%}) of 145 non-ASCT patients had CMV PCR positive specimens. Among non-ASCT patients with positive CMV PCR results, 10 patients were asymptomatic, 14 had symptomatic reactivation, while 2 had CMV disease. In the ASCT group, 42 (33.3 {\%}) patients had CMV PCR positive samples. CMV reactivation was asymptomatic in 34 (81 {\%}) cases, and 8 (19 {\%}) patients had symptomatic reactivation. In the non-ASCT group, the rate of CMV infection is low. In the ASCT group, the prevalence of CMV infection was higher than in the non-ASCT group, but the majority of CMV infection was asymptomatic and only small number of patients had symptomatic reactivation. Thus, our results also showed that the use of routine CMV DNA monitoring is not necessary in patients with haematological malignancies not receiving fludarabine-containing regimen or alemtuzumab, in spite of this to decrease the mortality we have to consider the use of molecular tests in case of suspected infectious conditions.",
keywords = "Cytomegalovirus, Diagnosis, Immunocompromised, Molecular",
author = "Kl{\'a}ra Piukovics and Gabriella Terhes and T{\'i}mea Gurbity-P{\'a}lfi and {\'A}gnes Bereczki and Ferenc R{\'a}rosi and Judit De{\'a}k and Zita Borb{\'e}nyi and E. Urb{\'a}n",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/s00277-016-2831-7",
language = "English",
volume = "96",
pages = "125--131",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Cytomegalovirus infection in patients with haematological diseases and after autologous stem cell transplantation as consolidation

T2 - a single-centre study

AU - Piukovics, Klára

AU - Terhes, Gabriella

AU - Gurbity-Pálfi, Tímea

AU - Bereczki, Ágnes

AU - Rárosi, Ferenc

AU - Deák, Judit

AU - Borbényi, Zita

AU - Urbán, E.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Because of the widespread use of immunosuppressive drugs, CMV infection is one of the most important causes of morbidity and mortality in patients with haematological malignancies worldwide. The aim of the study was to retrospectively analyse the epidemiology of CMV infection in haematological patients. Between 2008 and 2014, 1238 quantitative CMV DNA detections from plasma specimens were performed. These specimens were collected from 271 patients with haematological malignancy. Patients were grouped on the basis of underlying diseases (lymphoid and myeloid malignancies and other haematological diseases). In the lymphoid and myeloid groups, we distinguished ASCT and non-ASCT groups. During the studied period, the majority of examined patients (82.6 %) were treated with lymphoproliferative disease. A total of 126 (46.5 %) patients underwent ASCT, while 145 (53.5 %) did not have stem cell transplantation. A total of 118 (9.5 %) of 1238 plasma specimens proved to be positive for CMV DNA; these specimens were collected from 66 (24.4 %) patients. Twenty-four (16.6 %) of 145 non-ASCT patients had CMV PCR positive specimens. Among non-ASCT patients with positive CMV PCR results, 10 patients were asymptomatic, 14 had symptomatic reactivation, while 2 had CMV disease. In the ASCT group, 42 (33.3 %) patients had CMV PCR positive samples. CMV reactivation was asymptomatic in 34 (81 %) cases, and 8 (19 %) patients had symptomatic reactivation. In the non-ASCT group, the rate of CMV infection is low. In the ASCT group, the prevalence of CMV infection was higher than in the non-ASCT group, but the majority of CMV infection was asymptomatic and only small number of patients had symptomatic reactivation. Thus, our results also showed that the use of routine CMV DNA monitoring is not necessary in patients with haematological malignancies not receiving fludarabine-containing regimen or alemtuzumab, in spite of this to decrease the mortality we have to consider the use of molecular tests in case of suspected infectious conditions.

AB - Because of the widespread use of immunosuppressive drugs, CMV infection is one of the most important causes of morbidity and mortality in patients with haematological malignancies worldwide. The aim of the study was to retrospectively analyse the epidemiology of CMV infection in haematological patients. Between 2008 and 2014, 1238 quantitative CMV DNA detections from plasma specimens were performed. These specimens were collected from 271 patients with haematological malignancy. Patients were grouped on the basis of underlying diseases (lymphoid and myeloid malignancies and other haematological diseases). In the lymphoid and myeloid groups, we distinguished ASCT and non-ASCT groups. During the studied period, the majority of examined patients (82.6 %) were treated with lymphoproliferative disease. A total of 126 (46.5 %) patients underwent ASCT, while 145 (53.5 %) did not have stem cell transplantation. A total of 118 (9.5 %) of 1238 plasma specimens proved to be positive for CMV DNA; these specimens were collected from 66 (24.4 %) patients. Twenty-four (16.6 %) of 145 non-ASCT patients had CMV PCR positive specimens. Among non-ASCT patients with positive CMV PCR results, 10 patients were asymptomatic, 14 had symptomatic reactivation, while 2 had CMV disease. In the ASCT group, 42 (33.3 %) patients had CMV PCR positive samples. CMV reactivation was asymptomatic in 34 (81 %) cases, and 8 (19 %) patients had symptomatic reactivation. In the non-ASCT group, the rate of CMV infection is low. In the ASCT group, the prevalence of CMV infection was higher than in the non-ASCT group, but the majority of CMV infection was asymptomatic and only small number of patients had symptomatic reactivation. Thus, our results also showed that the use of routine CMV DNA monitoring is not necessary in patients with haematological malignancies not receiving fludarabine-containing regimen or alemtuzumab, in spite of this to decrease the mortality we have to consider the use of molecular tests in case of suspected infectious conditions.

KW - Cytomegalovirus

KW - Diagnosis

KW - Immunocompromised

KW - Molecular

UR - http://www.scopus.com/inward/record.url?scp=84991106971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991106971&partnerID=8YFLogxK

U2 - 10.1007/s00277-016-2831-7

DO - 10.1007/s00277-016-2831-7

M3 - Article

C2 - 27730340

AN - SCOPUS:84991106971

VL - 96

SP - 125

EP - 131

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 1

ER -